ELECLAZINE, элеклазин , إيليكلازين , 依来克秦 , REVISITED

New Drug Approvals

ELECLAZINE

GS-6615

Molecular Formula:	C21H16F3N3O3
Molecular Weight:	415.372 g/mol

1443211-72-0

4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one

4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3,4,5- tetrahydro-1,4- benzoxazepin-5-one

7-(4-(Trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one

1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl]-

Eleclazine; UNII-PUY08529FK; 1443211-72-0; GS-6615; PUY08529FK; 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-on

элеклазин [Russian] [INN]

إيليكلازين [Arabic] [INN]

依来克秦 [Chinese] [INN]

• Phase III Long QT syndrome

INGREDIENT	UNII	CAS
Eleclazine Hydrochloride	4R1JP3Q4HI	1448754-43-5

Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.

In 2015, orphan drug designation was assigned to the product by the FDA for the treatment of congenital long QT syndrome.

• Originator Gilead Sciences
• Class Antiarrhythmics; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Vasodilators
• Mechanism of Action Sodium channel antagonists

Highest Development Phases

• Phase III  Long QT syndrome
• Phase II/III Hypertrophic cardiomyopathy
• Phase II Ventricular arrhythmias
• No development reported 

View original post 2,322 more words